Dear Editor,

Posterior reversible encephalopathy syndrome (PRES) is a neurotoxic state characterized by acute neurological symptoms including headache, altered mental status, seizures, and visual disturbances, as well as distinct radiographic findings.[@B1] PRES lesions usually occur in association with vasogenic edema, and are reversible with appropriate management.[@B2] PRES can develop in diverse clinical settings such as renal failure, cytotoxic drugs, autoimmune disorders, and pre-eclampsia or eclampsia.[@B1] Here we report a very rare case of PRES that developed after carbamazepine treatment.

An 81-year-old male presented to the emergency department due to an altered mental status that had developed during the previous several hours. One day earlier he had visited the outpatient neurology clinic with a 1-week history of left occipital neuralgia, and had been started on oral carbamazepine (200 mg twice daily). He had a 9-year history of hypertension, which was well controlled with antihypertensive drugs including candesartan (4 mg/day), bisoprolol (1.25 mg/day), and torsemide (5 mg/day). He had no history of recent medication that might affect the mental status. An examination revealed that the patient had a stuporous mental status and blood pressures of 213/85 mm Hg. Routine blood tests revealed no abnormalities. Magnetic resonance imaging (MRI) of the brain showed bilateral posterior-predominant hyperintensities in T2-weighted fluid-attenuated inversion recovery imaging ([Fig. 1A, B, and C](#F1){ref-type="fig"}), with no diffusion restriction in diffusion-weighted imaging. The carbamazepine level was 9.0 µg/mL (therapeutic range, 4 to 12 µg/mL), and the drug was discontinued considering the possibility of its adverse effects. The patient was started on intravenous (IV) antihypertensive therapy, after which his blood pressure gradually decreased, normalizing without IV antihypertensive medications on day 5. On day 7 he was oriented and able to walk without assistance. Repeated brain MRI performed on day 13 showed that the vasogenic edema had almost completely resolved ([Fig. 1D, E, and F](#F1){ref-type="fig"}), a finding consistent with PRES. On day 14 the patient was discharged after his symptoms had fully resolved.

The clinical course and radiological features of our patient were compatible with the diagnosis of PRES.[@B1] To the best of our knowledge, this is the second case report showing PRES associated with carbamazepine administration. Furuta et al.[@B3] were the first to report the development of PRES induced by carbamazepine, which was in a 21-year-old male. Because carbamazepine is commonly administered in various neurological disorders such as epilepsy, trigeminal neuralgia, and neuromyelitis optica spectrum disorder related tonic spasms, neurologists should be aware that this drug can induce PRES, even when it is administered within the therapeutic range.

Although the exact pathomechanism of PRES remains unclear, one hypothesis is that severe hypertension induces impairment of cerebrovascular autoregulation, vasodilatation, and vasogenic edema, resulting in PRES.[@B1] In the present case, PRES appeared to be attributed to the carbamazepine-induced severe hypertension exceeding the capabilities of cerebral autoregulation. Carbamazepine can cause various cardiovascular effects including acute increases in the blood pressure in rare cases.[@B4][@B5][@B6] Hypertension induced by carbamazepine occasionally leads to the development of a hypertensive crisis, which was strongly suspected in our case. The potential mechanisms underlying carbamazepine-induced hypertension include altered antidiuretic hormone and changes in central noradrenergic mechanism.[@B4] Because carbamazepine-induced hypertension is rare, we cannot exclude the possibility that carbamazepine is simply a bystander. However, given the temporal relationship between carbamazepine initiation and the development of PRES and the absence of other risk factors for PRES, this bias was not likely to be significant.

None.
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![MRI of posterior reversible encephalopathy syndrome. Brain MRI revealed high signal intensities predominantly in the bilateral posterior brain regions in T2-weighted fluid-attenuated inversion recovery imaging (A, B, and C). Repeated brain MRI on day 13 showed that the abnormalities had almost completely resolved (D, E, and F). MRI: magnetic resonance imaging.](jcn-16-502-g001){#F1}
